Kinetics and 28-day test–retest repeatability and reproducibility of [11C]UCB-J PET brain imaging

Tuncel, H., Boellaard, R., Coomans, E. M., de Vries, E. FJ., Glaudemans, A. WJM., Feltes, P. K., García, D. V., Verfaillie, S. CJ., Wolters, E. E., Sweeney, S. P., Ryan, J. M., Ivarsson, M., Lynch, B. A., Schober, P., Scheltens, P., Schuit, R. C., Windhorst, A. D., De Deyn, P. P., van Berckel, B. NM. & Golla, S. SV., Oct-2020, In : Journal of Cerebral Blood Flow and Metabolism. 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

[11C]UCB-J is a novel radioligand that binds to synaptic vesicle glycoprotein 2A (SV2A). The main objective of this study was to determine the 28-day test–retest repeatability (TRT) of quantitative [11C]UCB-J brain positron emission tomography (PET) imaging in Alzheimer’s disease (AD) patients and healthy controls (HCs). Nine HCs and eight AD patients underwent two 60 min dynamic [11C]UCB-J PET scans with arterial sampling with an interval of 28 days. The optimal tracer kinetic model was assessed using the Akaike criteria (AIC). Micro-/macro-parameters such as tracer delivery (K1) and volume of distribution (VT) were estimated using the optimal model. Data were also analysed for simplified reference tissue model (SRTM) with centrum semi-ovale (white matter) as reference region. Based on AIC, both 1T2k_VB and 2T4k_VB described the [11C]UCB-J kinetics equally well. Analysis showed that whole-brain grey matter TRT for VT, DVR and SRTM BPND were –2.2% ± 8.5, 0.4% ± 12.0 and –8.0% ± 10.2, averaged over all subjects. [11C]UCB-J kinetics can be well described by a 1T2k_VB model, and a 60 min scan duration was sufficient to obtain reliable estimates for both plasma input and reference tissue models. TRT for VT, DVR and BPND was <15% (1SD) averaged over all subjects and indicates adequate quantitative repeatability of [11C]UCB-J PET.

Original languageEnglish
Number of pages13
JournalJournal of Cerebral Blood Flow and Metabolism
Publication statusPublished - Oct-2020


  • 11c, accepted 27 september 2020, alzheimer, kinetic modelling, pet, received 11 march 2020, revised 19 august 2020, s disease, sv2a, ucb-j

ID: 136222629